<DOC>
	<DOCNO>NCT02237950</DOCNO>
	<brief_summary>A double-blind , phase 3 study determine efficacy SPL7013 Gel administer alternate day 16 week , compare placebo gel prevent recurrence BV woman history recurrent BV .</brief_summary>
	<brief_title>Efficacy Safety Study SPL7013 Gel Prevent Recurrence Bacterial Vaginosis ( BV )</brief_title>
	<detailed_description>Eligible participant , history recurrent BV current episode BV , receive seven-day course oral metronidazole . Participants successfully treat BV , continue eligible , randomly assign receive either 1 % SPL7013 Gel placebo gel alternate day bed-time 16 consecutive week . The primary endpoint determine conclusion 16 week treatment phase . Participants experience BV recurrence consider complete study . Such participant receive BV treatment line local practice attend study visit . Participants successfully reach Week 16 without BV recurrence enter 12-week follow-up phase Week 28 . Participants attend study visit 4-weekly interval throughout duration study Week 28 ( point BV recurrence ) ass recurrence BV adverse event .</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Vaginosis , Bacterial</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>Current active episode BV ( diagnosis define : At least 3 4 Amsel criterion ; Nugent score least 4 ; presence BVrelated symptom ) History recurrent BV ( least 3 episode previous year include current episode ) Using effective method contraception Test positive sexually transmitted infection Presence genital Herpes Simplex Virus ( HSV ) lesion Human Papilloma Virus ( HPV ) lesion require treatment Abnormal pelvic exam , include presence vaginal urinary tract infection Pregnancy</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>